Found 223 clinical trials
COVID-19 Treatment Trial: Investigational Medication as a Non-antiviral Immunomodulator
. - Arm A: CD24Fc / Best Available Treatment - Arm B: placebo / Best Available Treatment CD24Fc will be administered as single dose of 480 mg via IV infusion on
- 4013 views
- 17 Jun, 2020
- 4 locations
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with
- 78 views
- 24 Jan, 2020
- 1 location
Alpha-Synuclein Kinetics
cleared from the body), we will use 3 proven approaches to determine this. 10 days of oral-labeling followed by 5 subsequent LPs 16 hours of IV infusion of the label, one lumbar
- 49 views
- 24 Jan, 2020
- 1 location
Lilly H0P-MC-CPMP – BACK PAIN
participants will receive the study medication and one out of every three will be receive a placebo. The medication is given by an intravenous (IV) infusion every 2 weeks for a total of 4 infusions. Participants
- 87 views
- 23 Nov, 2020
- 1 location
Do You Suffer From Osteoarthritis Of The Knee?
Do You Suffer From Osteoarthritis Of The Knee?
- 620 views
- 08 Nov, 2020
- 1 location
Do You Experience Painful Diabetic Neuropathy?
We are currently seeking volunteers who are diagnosed with Diabetic Peripheral Neuropathic Pain and who experience pain daily. This is a study of a new investigational medication that may help to relieve the pain of Diabetic Neuropathy.
- 97 views
- 23 Nov, 2020
- 1 location
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)
- 82 views
- 25 Mar, 2021
- 1 location
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy
- 167 views
- 08 Nov, 2020
- 1 location
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is How This Combination Affects the Body the Maximum Amount That Can be Given How it Moves Into Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
) infusion. An IV infusion is given through a needle into a vein. This study will have two parts. The first part will help find the most appropriate dose that can be given in the second part.
- 0 views
- 18 Sep, 2021
- 16 locations
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
, patients will receive 375 mg/m2 of rituximab (US, Canada – Rituxan®; EU - Mabthera®), given as an IV infusion once weekly for 4 weeks. In Arm B, patients will receive Iodine I 131 Tositumomab
- 24 views
- 07 Nov, 2020
- 4 locations